<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3329">
  <stage>Registered</stage>
  <submitdate>20/10/2011</submitdate>
  <approvaldate>20/10/2011</approvaldate>
  <nctid>NCT01458119</nctid>
  <trial_identification>
    <studytitle>Open-Label Phase 3 Long-Term Safety Study of Migalastat</studytitle>
    <scientifictitle>An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease</scientifictitle>
    <utrn />
    <trialacronym>AT1001-041</trialacronym>
    <secondaryid>AT1001-041</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fabry Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - migalastat HCl 150mg

Experimental: migalastat HCl 150 mg - Migalastat HCl s provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.


Treatment: drugs: migalastat HCl 150mg
Provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events (AEs) - non-serious AEs, serious AEs, and possible suicidality related AEs</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Withdrawal from treatment due to AEs - including non-serious and serious AEs</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in vital signs - blood pressure, heart rate</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in laboratory parameters - blood chemistry, hematology, urinalysis</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in electrocardiogram (ECG) - 12-lead ECG</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in echocardiography (ECHO) - ECHO ultrasound</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Estimated glomerular filtration rate - based on the Modification of Diet in Renal Disease equation</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Measurement of 24-hour urine - protein, albumin, creatinine and globotriaosylceramide (GL-3)</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of left ventricular mass index and ejection fraction - as measured by echocardiography</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of leukocyte alpha-galactosidase A (a-Gal A) activity - enzyme responsible for breaking down GL-3</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of patient reported assessment of pain - as assessed by the Brief Pain Inventory short form</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of patient reported Quality of Life - as assessed by the Short Form-36 survey</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Completed migalastat HCl treatment in a previous Fabry disease protocol

          -  Both: both female and male participants are being studied

          -  Ages 16 years or older

          -  Males and females must agree to use protocol identified acceptable contraception</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Estimated glomerular filtration rate in the previous study was &lt;30 mL/min/1.73m2;
             unless there is measured GFR available within 3 months of Baseline Visit (Visit 1),
             which is &gt;30 mL/min/1.73m2

          -  Has undergone, or is scheduled to undergo kidney transplantation or is currently on
             dialysis

          -  Pregnancy or breast feeding

          -  Treated with another investigational drug (except migalastat HCl) within 30 days of
             study start

          -  Unable to comply with study requirements, or deemed otherwise unsuitable for study
             entry, in the opinion of the investigator

          -  Has documented transient ischemic attack, stroke, unstable angina, or myocardial
             infarction within the 12 months before Visit 1

          -  Has clinically significant unstable cardiac disease in the opinion of the investigator

          -  Has history of allergy or sensitivity to AT1001 (including excipients) or other
             iminosugars

          -  Requires treatment with Glyset, (miglitol), or Zavesca (miglustat)

          -  Has any intercurrent illness or condition that may preclude the subject from
             fulfilling the protocol requirements

          -  Patients with severe or unsuitable concomitant medical condition

          -  Patients with clinically significant abnormal laboratory value(s) and clinically
             significant electrocardiogram (ECG) findings at baseline.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>85</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Women's and Children's Hospital - North Adelaide</hospital>
    <postcode>3050 - Parkville</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Pilar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Garches</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amicus Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a long term, open label study of migalastat HCl (AT1001) in subjects with Fabry
      disease who completed treatment in a previous monotherapy trial with migalastat hydrochloride
      (HCl).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01458119</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor, Clinical Research</name>
      <address>Amicus Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>